Existing HT CBB Kit Enables High-Throughput Extraction of HMW DNA Tailored for HiFi With an Updated Workflow for Animal Blood and Bacteria
MENLO PARK, Calif., Jan. 15, 2024 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PanDNA, a versatile Nanobind DNA extraction kit. This new offering expands the array of sample types suitable for long-read sequencing, including cells, bacteria, blood, tissue, plant nuclei, and insects.
Nanobind kits are designed for researchers to efficiently extract high-quality, high molecular weight DNA across a wide range of sample types. These kits are versatile, accommodating both manual (Nanobind PanDNA kit) and high-throughput (Nanobind CBB HT kit) settings. Their simple, rapid protocol is compatible with platforms from PacBio’s Compatible automation providers.
In addition, based on customer feedback, the existing high-throughput extraction Nanobind HT CBB kit will now support two new sample types – animal blood and bacteria – and can accommodate 96 samples per run.
"The new PanDNA kit will be the go-to kit for extracting DNA optimized for HiFi sequencing," said Jeff Eidel, Chief Commercial Officer at PacBio. "We continue to enable our customers with products such as the PanDNA kit that support researchers to complete accurate genome assemblies, identify structural variants, and explore complex biological systems in extraordinary detail using our Revio sequencing system."
"Nanobind high molecular weight DNA extraction is a game-changer for us and having one universal kit for all supported samples is very convenient," said Igor Stevanovski, Research Assistant at the Genomic Technologies Lab, Garvan Institute of Medical Research – one of Australia’s premier medical research institutes. "The flexibility offered by the PanDNA kit will support our broad research community to answer those key questions and make important biological discoveries."
"The Darwin Tree of Life project aims to generate high quality genomes for 70,000 species of plants, fungi, animals and protists across Britain and Ireland. High-throughput solutions such as the Nanobind CBB HT kit are critical for efforts like these," said Caroline Howard, Senior Scientific Manager, Tree of Life Programme at the Wellcome Sanger Institute. "The Nanobind kits combined with the Revio system address these needs by significantly increasing throughput. Using the kits, we were able to generate 30x coverage of HiFi data sufficient for de novo assembly."
The new PanDNA kit is expected to be available for purchase and shipment in February 2024. The Nanobind HT CBB kit is available now. For more information, visit the Nanobind extraction kit page here.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to future availability, uses, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, including Nanobind PanDNA kits; statements regarding DNA extraction across a wide range of sample types; PanDNA kits as a go-to kit for HiFi sequencing and its ability to support a broad research community; among other future events. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this press release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. These risks include, but are not limited to, challenges inherent in developing, manufacturing, launching, marketing and selling new products; potential product performance and quality issues and potential delays in development and commercialization timelines; rapidly changing technologies and extensive competition in genomic sequencing that could make the products PacBio is developing obsolete or non-competitive; and third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio’s patents or proprietary rights. Readers are strongly encouraged to read the full cautionary statements contained in PacBio’s filings with the Securities and Exchange Commission, including the risks set forth in PacBio’s Forms 8-K, 10-K, and 10-Q. PacBio disclaims any obligation to update or revise any forward-looking statements.
Contacts
Investors:
Todd Friedman
ir@pacificbiosciences.com
Media:
Lizelda Lopez
pr@pacificbiosciences.com
SOURCE Pacific Biosciences of California, Inc.